# Comprehensive Faculty Q&A Bank: Decompensated Chronic Liver Disease ### Compiled from Previous Case Presentation Sessions — Postgraduate Internal Medicine --- ## FROM RABIN MAHARJAN'S CASE (46F, Ascites + Bilateral Leg Swelling + SOB) --- **Q1. If ascites is the first presentation → bad prognosis. If UGI bleed → better prognosis. Explain this paradox.** **Answer:** This is a well-established clinical observation rooted in the natural history of cirrhosis and the BAVENO consensus. **Ascites as first decompensation → worse prognosis:** Ascites signifies severe portal hypertension (HVPG ≥12 mmHg) combined with profound hepatic synthetic failure (low albumin → reduced oncotic pressure) and neurohormonal activation (RAAS, SNS, ADH). The 1-year mortality after first ascites is **20–40%** and 5-year mortality is **50%** (EASL CPG 2018). Ascites also predicts future complications — SBP (25–30%/year), HRS (18%/year), and HE — creating a downward spiral. **Variceal bleed as first decompensation → relatively better prognosis:** Variceal bleeding can occur even at a relatively preserved hepatic synthetic function (Child A/B), triggered by a threshold HVPG ≥12 mmHg alone, without necessarily requiring the degree of hepatocellular dysfunction that ascites demands. A Child A patient bleeding from varices has a 6-week mortality of ~5–10%, whereas a Child C patient with ascites has far higher short-term mortality. The **CANONIC study (Moreau et al., *Hepatology* 2013)** showed that among decompensation events, ascites alone conferred the worst median transplant-free survival. > **Reference:** EASL CPG Decompensated Cirrhosis, *J Hepatol* 2018; D'Amico G et al., *J Hepatol* 2014. --- **Q2. Add history of malnutrition — why is this important?** **Answer:** Malnutrition is present in **50–90% of cirrhotics** and is an independent predictor of mortality, complications (infections, HE, poor wound healing), and post-transplant outcomes. **Pathophysiology in cirrhosis:** - Reduced glycogen stores → accelerated starvation (overnight fast equivalent to 3-day fast in healthy person). - Protein catabolism: reduced branched-chain amino acids (BCAA), elevated aromatic amino acids (Fischer ratio) → HE risk. - Zinc deficiency → impaired urea cycle → hyperammonaemia. - Fat malabsorption → deficiency of fat-soluble vitamins (A, D, E, K). - Sarcopenia (reduced skeletal muscle mass) → independently predicts 6-month mortality (Montano-Loza et al., *Hepatology* 2012). **How to assess:** - **Royal Free Hospital Global Assessment (RFH-GA):** Validated for cirrhosis; includes BMI, mid-arm circumference, dietary intake. - **Handgrip strength** (dynamometry): Sarcopenia marker; <30 kg (men) = significant. - **DEXA scan / CT L3 skeletal muscle index:** Research tool for sarcopenia quantification. **Management:** - Caloric target: 35–40 kcal/kg/day; protein: 1.2–1.5 g/kg/day (protein restriction is OBSOLETE in cirrhosis). - Late evening snack (LES): 50g complex carbohydrate at bedtime — reduces overnight fasting catabolism. - BCAA supplementation if protein-intolerant. > **Reference:** ESPEN Guidelines on Liver Disease, *Clinical Nutrition* 2019; Montano-Loza AJ et al., *Hepatology* 2012. --- **Q3. Budd-Chiari Syndrome (BCS) as a presentation — what is it, and what causes it? What is HVOTO?** **Answer:** **Budd-Chiari Syndrome** is defined as hepatic venous outflow tract obstruction (HVOTO) at any level from the small hepatic venules to the right atrium, excluding cardiac causes (e.g., constrictive pericarditis, right heart failure). **Classification:** - Primary BCS: Thrombosis of hepatic veins / IVC due to underlying thrombophilia. - Secondary BCS: Tumour invasion (HCC, renal cell carcinoma), web/membrane. **Causes (mnemonic: MPN-HAP):** - Myeloproliferative Neoplasms (JAK2 V617F mutation) — most common (40–50%); polycythaemia vera is the single largest cause. - Paroxysmal Nocturnal Haemoglobinuria (PNH). - Antiphospholipid Syndrome. - Inherited thrombophilias: Factor V Leiden, Prothrombin G20210A, Protein C/S/ATIII deficiency. - Pregnancy/OCP use. - Behçet's disease (IVC involvement particularly). - Abdominal malignancy (extrinsic compression/invasion). **Clinical triad:** Abdominal pain + hepatomegaly + ascites (massive, exudative, high protein). Unlike cirrhotic ascites (which is transudative), BCS ascites has SAAG ≥1.1 g/dL but protein >2.5 g/dL. **Diagnosis:** Triphasic CT / MRI — shows caudate lobe hypertrophy (independent venous drainage via accessory hepatic veins to IVC), absent/thrombosed hepatic veins, "flip-flop" enhancement pattern. Doppler USG: absent hepatic vein flow, spider-web pattern. **HVOTO = Hepatic Venous Outflow Tract Obstruction** — the pathophysiological umbrella term encompassing BCS at any level. > **Reference:** EASL CPG Vascular Diseases of the Liver, *J Hepatol* 2016; DeLeve LD et al., *Hepatology* 2009. --- **Q4. How do you take BMI in an oedematous/ascitic patient?** **Answer:** Standard BMI (weight/height²) is **unreliable** in oedematous or ascitic patients because measured weight includes fluid weight (ascites + peripheral oedema), overestimating true lean body mass. **Approaches:** 1. **Estimated dry weight:** Subtract estimated fluid weight. Clinically estimate ascites volume (mild ~1–2L, moderate ~4–6L, tense ~8–12L) and oedema weight (~1–2L per grade of bilateral pitting oedema). - `Dry weight = Actual weight − Ascites weight − Oedema weight` 2. **Mid-arm circumference (MAC) and mid-arm muscle circumference (MAMC):** Not affected by fluid distribution. MAMC = MAC − (π × triceps skinfold thickness). Better nutritional marker. 3. **Handgrip strength (HGS):** Dynamometry — functional measure of muscle mass. Validated surrogate for sarcopenia in cirrhosis. 4. **Post-paracentesis weight:** Weigh the patient after large-volume paracentesis for closer approximation. 5. **Bioelectrical Impedance Analysis (BIA):** Can estimate lean body mass, but accuracy is limited in significant ascites. **Practical point:** ESPEN 2019 recommends using **subjective global assessment (SGA) or RFH-GA** rather than BMI alone for nutritional assessment in cirrhosis. > **Reference:** ESPEN Guidelines on Liver Disease, *Clinical Nutrition* 2019. --- **Q5. What is the minimum amount and duration of alcohol required to develop CLD?** **Answer:** This is a critical question with a nuanced, gender-differentiated answer. **Threshold quantities (EASL ALD Guidelines 2018, updated 2023):** | Parameter | Men | Women | |---|---|---| | Minimum "significant" intake | >21 units/week (210g/week) | >14 units/week (140g/week) | | Threshold for ALD risk | >30g/day for >5 years | >20g/day for >5 years | | High-risk for cirrhosis | >60–80g/day for >10 years | >20–40g/day for >10 years | **1 unit = 8–10g of pure alcohol** (UK definition); 1 standard drink (USA) = 14g. **Key concepts:** - Women develop ALD at **lower doses and shorter durations** — due to lower gastric ADH activity, higher body fat percentage (less volume of distribution for ethanol), and oestrogen-mediated enhanced hepatotoxicity. - Only **~10–15% of heavy drinkers** develop cirrhosis → genetic susceptibility (PNPLA3 I148M polymorphism most studied), nutritional status, obesity, and viral co-infection are major modifiers. - **Pattern of drinking** matters: binge drinking (>60g in a session) is more hepatotoxic than equivalent daily intake. - **Total lifetime dose** (grams of alcohol × years) correlates best with fibrosis progression. **This patient:** 110g/day × 25 years = extremely high lifetime dose (nearly 10× the risk threshold). Developing CLD is expected; the surprise is that only 10–15% of such drinkers progress to cirrhosis without co-factors. > **Reference:** EASL CPG on Alcohol-Related Liver Disease, *J Hepatol* 2018; AASLD Guidance on Alcohol-Associated Liver Disease, *Hepatology* 2023. --- **Q6. In summary → examination findings. After Hx & Examination → Differential. CLD → other causes in history (autoimmune, ethanol...)** **Answer:** **Systematic approach to CLD aetiology from History + Examination:** **From History — Aetiological clues:** | Aetiology | Key Historical Feature | |---|---| | Alcoholic | Quantified alcohol (>30g/day >5 years), parotid enlargement, Dupuytren's | | HBV | Perinatal exposure, endemic area, prior transfusion, tattooing, IVDU | | HCV | IVDU, needle-stick, prior transfusion (pre-1992 screening) | | NAFLD/MAFLD | Metabolic syndrome (obesity, T2DM, dyslipidaemia, HTN) | | Autoimmune Hepatitis (AIH) | Young/middle-aged female, other autoimmune disease (thyroiditis, IBD, RA), fluctuating jaundice | | PBC | Middle-aged female, pruritus preceding jaundice, sicca symptoms, xanthelasma | | PSC | Male, IBD (UC > CD), recurrent cholangitis | | Wilson's Disease | Age <40, neuropsychiatric features, Kayser-Fleischer rings, haemolytic anaemia | | Haemochromatosis | Diabetes + "bronze diabetes", arthropathy (2nd-3rd MCP), hypogonadism, cardiomyopathy | | α1-AT deficiency | Emphysema + liver disease, non-smoker, family history | | Budd-Chiari | Thrombophilia risk factors, IVC obstruction symptoms | **From Examination — Stigmata pointing to specific aetiologies:** - Dupuytren's contracture, parotid enlargement, loss of body hair, testicular atrophy → Alcohol. - Kayser-Fleischer rings (slit-lamp) → Wilson's disease. - Xanthelasma + scratch marks → PBC. - Slate-grey skin pigmentation + hepatomegaly → Haemochromatosis. - Emphysematous chest + clubbing → α1-AT deficiency. > **Reference:** Harrison's Principles of Internal Medicine, 22nd ed., Ch. 429 (Cirrhosis). --- **Q7. Ascites → due to decreased liver synthetic function. Portal vein thrombosis → causes UGI bleed but NOT ascites. Explain.** **Answer:** **Why PVT causes UGI bleed but typically NOT ascites:** Portal vein thrombosis causes **pre-hepatic portal hypertension**. The key distinction: - In **pre-hepatic** PVT: Portal pressure is elevated upstream of the liver; but **hepatic synthetic function is normal** (the liver parenchyma is intact and receives adequate arterial blood). Sinusoidal pressure and hepatic venous pressure are NOT elevated. Therefore, the oncotic-hydrostatic balance within the liver sinusoids (the driver of ascites formation) is preserved. UGI bleeding (varices) occurs because the portal-systemic collateral pathways open under elevated portal pressure. - In **cirrhotic portal hypertension** (sinusoidal/post-sinusoidal): Both portal pressure AND sinusoidal hydrostatic pressure are elevated. Combined with hypoalbuminaemia (reduced oncotic pressure), RAAS activation, and splanchnic vasodilation → ascites forms via Starling forces imbalance + sodium/water retention. **The "overflow vs. underfill" debate:** - Classic "underfill theory": reduced plasma oncotic pressure → fluid leaks → reduced effective circulatory volume → RAAS activation. - Modern "overflow theory": Primary renal sodium retention (peripheral arterial vasodilation hypothesis, Schrier et al.) → volume expansion → ascites. - Current consensus: **Splanchnic arterial vasodilation** (nitric oxide-mediated) → reduced effective arterial blood volume → baroreceptor-mediated RAAS/SNS activation → renal sodium and water retention → ascites + oedema. This requires BOTH portal hypertension AND hepatic dysfunction. **Clinical pearl:** A patient with isolated PVT (e.g., from septic thrombosis) rarely develops ascites unless there is concurrent hepatocellular disease. > **Reference:** Schrier RW et al. (*NEJM* 1988); Ginès P & Schrier RW (*NEJM* 2009). --- **Q8. Basal rate = 80% of total daily dose, in TPN over 24hr; bolus → in fluid. 30–34 = basal; 50 = regular. (Insulin management in CLD)** **Answer:** This refers to **insulin management in cirrhosis-related diabetes (Hepatogenous Diabetes)** or management of pre-existing diabetes in CLD, particularly when a patient is on TPN/parenteral nutrition. **Hepatogenous Diabetes:** - Occurs in 30–60% of cirrhotics; caused by peripheral insulin resistance + impaired hepatic glucose metabolism + decreased incretin response. - Differs from T2DM: less macrovascular risk, more HE risk (due to hypoglycaemia from impaired gluconeogenesis), and distinct management. **Insulin management in CLD + TPN:** **Rule: In TPN, 80% of the total daily insulin dose is given as basal (added to TPN bag over 24 hours); 20% is given as correction boluses in IV fluid or subcutaneously.** - Target glucose: **140–180 mg/dL** (7.8–10 mmol/L) in most hospitalised patients (ADA 2024). - In cirrhosis, **hypoglycaemia risk is high** (impaired glycogenolysis + gluconeogenesis) — tighter targets (<140) are NOT recommended. - **Regular insulin** (30–34 units basal) added to TPN bag; regular insulin (50 units) may refer to correction scale. - Monitor glucose q4–6 hourly during TPN. **Oral agents in cirrhosis:** - **Metformin:** Contraindicated in Child C (lactic acidosis risk). - **Sulphonylureas:** High hypoglycaemia risk; avoid. - **SGLT2i:** Avoid (risk of euglycaemic DKA, UTI in immunocompromised). - **Insulin** remains the safest agent in advanced CLD. > **Reference:** ADA Standards of Care in Diabetes 2024, Section 16 (Diabetes in Hospital); EASL CPG Decompensated Cirrhosis 2018. --- **Q9. DDP → Decompensated CLD / CTD / Malnutrition / Disseminated TB / Disseminated Malignancy (ovarian tumour). Examination → PR examination, Breast examination necessary in ascites.** **Answer:** **Complete differential diagnosis of ascites — SAAG-based framework:** **High SAAG (≥1.1 g/dL) — Portal hypertension-related:** - Cirrhosis (most common, ~80%) - Alcoholic hepatitis - Cardiac ascites (right heart failure, constrictive pericarditis, tricuspid regurgitation) - Budd-Chiari Syndrome - Sinusoidal obstruction syndrome (SOS/VOD) - Massive hepatic metastases - Portal vein thrombosis (without cirrhosis — rare to cause ascites) **Low SAAG (<1.1 g/dL) — Non-portal hypertension:** - Peritoneal TB (most important in Nepal/South Asia) - Peritoneal carcinomatosis (ovarian, gastric, colorectal, breast, pancreatic) - Mesothelioma - Pancreatitis / pancreatic ascites - Lymphatic leak (chylous ascites) - Nephrotic syndrome (SAAG low, protein low) - Serositis (SLE, other CTD) **Why PR and breast examination are mandatory in unexplained ascites:** In any woman presenting with ascites without obvious liver disease, **ovarian malignancy** (Krukenberg tumours, papillary serous carcinoma) must be excluded —